Insmed (INSM)
NASDAQ:INSM
INSM Stock Chart & Stats
$143.98
-$1.02(-1.54%)
At close: 4:00 PM EST
$143.98
-$1.02(-1.54%)
Day’s Range― - ―
52-Week Range$60.40 - $212.75
Previous CloseN/A
Volume462.72K
Average Volume (3M)2.25M
Market Cap
$31.04B
Enterprise Value$30.25B
Total Cash (Recent Filing)$1.43B
Total Debt (Recent Filing)$768.16M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Apr 30, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding215,551,900
10 Day Avg. Volume2,036,736
30 Day Avg. Volume2,249,575
Financial Highlights & Ratios
PEG Ratio-1.93
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue49.88
Enterprise Value/Gross Profit62.82
Enterprise Value/Ebitda-25.71
Forecast
1Y Price Target
$207.23Price Target Upside43.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.71
Revenue Forecast (FY)$1.69B
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyLate-stage ENCORE trial results showed meaningful improvement in respiratory symptoms and durable bacterial culture conversion, supporting broader clinical effectiveness and expansion of the eligible patient population.
Commercial Uptake And ReimbursementStrong initial Brinsupri uptake combined with management keeping the list price unchanged and expecting favorable payer reimbursement supports potential revenue realization and could prompt a stock re-rating.
Regulatory PathwayCompany plans regulatory submissions in major markets to pursue conversion to traditional approval and label expansion, which could enable a broader commercial launch and increase the addressable market.
Bears Say
Commercial Concentration RiskHeavy investor focus on Brinsupri and minimal expected international sales concentrate near-term growth risk on US commercial execution, making the stock sensitive to underperformance in that launch.
Pricing And Payer Adoption RiskArikayce pricing appears less well-suited to frontline use, creating uncertainty about payer coverage and adoption versus existing generic standard therapies.
Safety And Endpoint RiskReported voice changes and higher cough rates raise tolerability concerns, and the subjective nature of the patient-reported respiratory symptom endpoint increases regulatory and payer risk.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $60.40 and its highest was $212.75 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $31.04B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Apr 30, 2026 which is in 36 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Feb 19, 2026. The company reported -$1.54 earnings per share for the quarter, missing the consensus estimate of -$1.072 by -$0.468.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.99.
How many shares outstanding does Insmed have?
Insmed has 215,551,900 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.54 in its last earnings report, missing expectations of -$1.072. Following the earnings report the stock price went up 6.545%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$207.23 (43.93% Upside)
$207.23 (43.93% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Negative
20 days / 200 days
Momentum
80.15%
12-Months-Change
Fundamentals
Return on Equity
-168.36%
Trailing 12-Months
Asset Growth
11.82%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM Company Deck
INSM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strongly positive commercial momentum driven by Brinsupri's launch (first full-quarter net revenue of $144.6M and guidance of at least $1B in 2026), solid ARIKAYCE growth (Japan +40% YoY) and a strong balance sheet (~$1.4B cash). Clinical progress (TPIP orphan designation and planned Phase III) and pipeline expansion via acquisitions were additional positives. Near-term challenges noted include early-stage depth of prescribing, some payer documentation requirements and increased operating spend (including ~$70M of one-time Q4 cash items). Management believes these lowlights are manageable and reiterated a path to cash flow positivity while retaining flexibility for selective business development. On balance, the highlights materially outweigh the lowlights.View all INSM earnings summariesINSM Stock 12 Month Forecast
Average Price Target
$207.23
▲(43.93% Upside)
Technical Analysis
Ownership Overview
0.76% Insiders
29.74% Mutual Funds
35.16% Other Institutional Investors
15.13% Public Companies and Individual Investors